Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 28, 2022; 28(28): 3555-3572
Published online Jul 28, 2022. doi: 10.3748/wjg.v28.i28.3555
Published online Jul 28, 2022. doi: 10.3748/wjg.v28.i28.3555
Gut microbiota alteration and modulation in hepatitis B virus-related fibrosis and complications: Molecular mechanisms and therapeutic inventions
Yao-Guang Li, Zu-Jiang Yu, Zhi-Gang Ren, Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
Yao-Guang Li, Zu-Jiang Yu, Ang Li, Gene Hospital of Henan Province, Precision Medicine Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
Zhi-Gang Ren, Jinan Microecological Biomedicine Shandong Laboratory, Jinan 250000, Shandong Province, China
Author contributions: Ren ZG and Li A designed the study; Li YG, Yu ZJ, Li A and Ren ZG collected data and summary viewpoints; Li YG wrote the manuscript; Ren ZG and Li A revised the manuscript; and All authors reviewed and approved the manuscript.
Supported by National Key Research and Development Program of China , No. 2018YFC2000500 ; Research Project of Jinan Microecological Biomedicine Shandong Laboratory , No. JNL-2022001A ; and National Natural Science Foundation of China , No. U2004121, No. 82070643 and No. U1904164.
Conflict-of-interest statement: All authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhi-Gang Ren, MD, PhD, Assistant Professor, Doctor, Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou 450052, Henan Province, China. fccrenzg@zzu.edu.cn
Received: April 4, 2022
Peer-review started: April 4, 2022
First decision: May 9, 2022
Revised: June 6, 2022
Accepted: June 24, 2022
Article in press: June 24, 2022
Published online: July 28, 2022
Processing time: 113 Days and 16.8 Hours
Peer-review started: April 4, 2022
First decision: May 9, 2022
Revised: June 6, 2022
Accepted: June 24, 2022
Article in press: June 24, 2022
Published online: July 28, 2022
Processing time: 113 Days and 16.8 Hours
Core Tip
Core Tip: Intimate connection between the gut microbiota alteration and hepatitis B virus (HBV)-related fibrosis and complications has been supported by animal and human studies. Researchers and clinicians are making effort to control and reverse fibrosis by rebuilding a healthy gut microbiota. We herein discuss the gut microbiota alteration in HBV-related fibrosis and therapies targeted on reconstruction of gut microbiota homeostasis.